These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16310074)

  • 21. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esthetic and cosmetic dermatology.
    Wollina U; Goldman A; Berger U; Abdel-Naser MB
    Dermatol Ther; 2008; 21(2):118-30. PubMed ID: 18394086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiological approaches to safety investigations.
    Wood JL; Adams VJ
    Vet Microbiol; 2006 Oct; 117(1):66-70. PubMed ID: 16713135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statin safety: an appraisal from the adverse event reporting system.
    Davidson MH; Clark JA; Glass LM; Kanumalla A
    Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botox: beyond cosmetic fixes. The procedure that revolutionized wrinkle treatment has myriad medical uses, many still experimental. What's the evidence?
    Harv Womens Health Watch; 2009 Sep; 17(1):1-3. PubMed ID: 19928628
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of military and civilian reporting rates for smallpox vaccine adverse events.
    McMahon AW; Zinderman C; Ball R; Gupta G; Braun MM
    Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):597-604. PubMed ID: 17154344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving self-reporting of adverse drug events in a West Virginia hospital.
    Schade CP; Hannah K; Ruddick P; Starling C; Brehm J
    Am J Med Qual; 2006; 21(5):335-41. PubMed ID: 16973950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report.
    Xiao Z; Zhang F; Cui Z
    Aesthetic Plast Surg; 2009 May; 33(3):409-12. PubMed ID: 19357910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxins for facial wrinkles: beyond glabellar lines.
    Dayan SH; Maas CS
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):41-9, vi. PubMed ID: 17317554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study.
    Lew HL; Lee EH; Castaneda A; Klima R; Date E
    Arch Phys Med Rehabil; 2008 Jan; 89(1):75-80. PubMed ID: 18164334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications.
    Borodic G
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):11-6, v. PubMed ID: 17317551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study.
    Cohen JL; Dayan SH
    J Drugs Dermatol; 2006; 5(7):596-601. PubMed ID: 16865863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short wait times for patients seeking cosmetic botulinum toxin appointments with dermatologists.
    Resneck JS; Lipton S; Pletcher MJ
    J Am Acad Dermatol; 2007 Dec; 57(6):985-9. PubMed ID: 17720277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.